- Ben: My personal passion is to be able to play a part in increasing the clinical success rates of new therapies for neurological diseases. I believe a critical way to accomplish this is with more clinically predictive models used in the selection of new therapeutic candidates, specifically with microphysiological systems (MPS). Animal models will always be crucial in biomedical research, but new technologies can help us define the models that are most applicable in specific contexts of use so that we optimize our research to improve clinical translatability. I was initially approached by several NA3RsC board members to develop an initiative to raise awareness in the community and disseminate the amazing ways in which MPS can be integrated into research programs both now and as the technologies continue to develop in the future.
- Ben: With our initiatives now humming and making impacts in their respective areas, I am excited to be of assistance to our amazing staff, led by Dr. Megan LaFollette, in building a sustainable plan for the organization to grow and increase its impact in the future.
- Ben: The NA3RsC MPS Initiative started with a small group of dedicated people, and now we are the first industry consortium in the MPS field, with 28 companies (and growing!) working together to advance the science and adoption of these technologies by researchers, drug developers and regulators around the world. I am excited to see the impact we can make together.
- Ben: In the short to medium term, I believe preclinical drug discovery programs will benefit with better designed studies and models to improve clinical translation. I also believe academic and industry scientists alike will benefit with resources aimed to improve reproducibility and ensure that animal and in vitro studies are done optimally, the first time. The NA3RsC’s efforts ultimately lead to more efficient, more translational science that benefits not only the animals on whom testing is performed but most importantly, the patients and society for whom our research is designed to benefit.
- NA3RsC President
- Chief Business Officer, AxoSim, Inc.
Founded in 2007, Scientist.com is the world’s leading scientific services marketplace. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies. Scientist.com operates private marketplaces for most of the world’s major pharmaceutical companies and the US NIH.